Evidence map›Paper›PMID 33361426›Full record

ArticleJournal of virology2021

Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA.

Christian Gaebler, Shane D Falcinelli, Elina Stoffel, Jenna Read, Ross Murtagh, Thiago Y Oliveira, Victor Ramos, Julio C C Lorenzi, Jennifer Kirchherr, Katherine S James and 8 more

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Journal of virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Christian Gaebler *Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.ORCID 0000-0001-7295-8128
Shane D Falcinelli *UNC HIV Cure Center, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0002-3554-226X
Elina StoffelLaboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.
Jenna ReadUNC HIV Cure Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Ross MurtaghUNC HIV Cure Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Thiago Y OliveiraLaboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.
Victor RamosLaboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.
Julio C C LorenziLaboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.
Jennifer KirchherrUNC HIV Cure Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Katherine S JamesUNC HIV Cure Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Brigitte AllardUNC HIV Cure Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Caroline BakerUNC HIV Cure Center, University of North Carolina, Chapel Hill, North Carolina, USA.
JoAnn D KurucUNC HIV Cure Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Marina CaskeyLaboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.
Nancie M ArchinUNC HIV Cure Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Robert F SilicianoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
David M MargolisUNC HIV Cure Center, University of North Carolina, Chapel Hill, North Carolina, USA dmargo@med.unc.edu nussen@rockefeller.edu.ORCID 0000-0001-5714-0002
Michel C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA dmargo@med.unc.edu nussen@rockefeller.edu.ORCID 0000-0003-0592-8564
University of North Carolina at Chapel Hill · USRockefeller University · USHoward Hughes Medical Institute · US

Funding

Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI MCELRATH, MARGARET JULIANA · 2012 to 2018
$131.5M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6M
Patient and Population Health Outcomes Research SWGP30AI124414 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Kathryn M. Anastos · 2017 to 2026
$28.3M
First-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5M
Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI126619 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARGOLIS, DAVID M. · 2016 to 2020
$23.2M
Optimization of Fc effector activity of anti-HIV antibodies to target HIV reservoirR01AI129795 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C, RAVETCH, JEFFREY VICTOR · 2017 to 2021
$4.2M
3BNC117 and 10-1074 to suppress HIV-1 replication and reduce the reservoirU01AI129825 · NIAID · ROCKEFELLER UNIVERSITY · PI CASKEY, MARINA · 2017 to 2021
$4.0M
The HIV Reservoir in Women: Implications for HIV cure interventionsR01AI134363 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ARCHIN, NANCIE MARIE · 2017 to 2020
$2.2M
Reducing the HIV Reservoir: Next-Generation Latency Reversal Agents and T Cell Population TargetsF30AI145588 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FALCINELLI, SHANE DAVID · 2019 to 2023
$217k
Howard Hughes Medical InstituteNCATS NIH HHS UL1 TR001866NIAID NIH HHS F30 AI145588NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI124414NIAID NIH HHS R01 AI129795NIAID NIH HHS R01 AI134363NIAID NIH HHS U01 AI129825NIAID NIH HHS UM1 AI100663NIAID NIH HHS UM1 AI126619NIAID NIH HHS UM1 AI126620
6 · The paper itself

Abstract

The HIV proviral reservoir is the major barrier to cure. The predominantly replication-defective proviral landscape makes the measurement of virus that is likely to cause rebound upon antiretroviral therapy (ART)-cessation challenging. To address this issue, novel assays to measure intact HIV proviruses have been developed. The intact proviral DNA assay (IPDA) is a high-throughput assay that uses two probes to exclude the majority of defective proviruses and determine the frequency of intact proviruses, albeit without sequence confirmation. Quadruplex PCR with four probes (Q4PCR) is a lower-throughput assay that uses limiting dilution long-distance PCR amplification followed by quantitative PCR (qPCR) and near-full-length genome sequencing (nFGS) to estimate the frequency of sequence-confirmed intact proviruses and provide insight into their clonal composition. To explore the advantages and limitations of these assays, we compared IPDA and Q4PCR measurements from 39 ART-suppressed people living with HIV. We found that IPDA and Q4PCR measurements correlated with one another, but frequencies of intact proviral DNA differed by approximately 19-fold. This difference may be in part due to inefficiencies in long-distance PCR amplification of proviruses in Q4PCR, leading to underestimates of intact proviral frequencies. In addition, nFGS analysis within Q4PCR explained that some of this difference is explained by proviruses that are classified as intact by IPDA but carry defects elsewhere in the genome. Taken together, this head-to-head comparison of novel intact proviral DNA assays provides important context for their interpretation in studies to deplete the HIV reservoir and shows that together the assays bracket true reservoir size.

Indexed as

Anti-Retroviral AgentsBase SequenceCD4-Positive T-LymphocytesDNA, ViralGenes, envGenome, ViralHIV-1HIV InfectionsMolecular Diagnostic TechniquesPolymerase Chain ReactionPolymorphism, GeneticProvirusesViral LoadViral Packaging SequenceVirus LatencyAnti-Retroviral AgentsDNA, ViralHIV cureHIV latent reservoirhuman immunodeficiency virus

Identifiers

PMID33361426
PMCPMC8094944
OpenAlexW3114403040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.